ID
45842
Descripción
Principal Investigator: Steven McCarroll, PhD, The Broad Institute of MIT and Harvard, Cambridge, MA, USA MeSH: Schizophrenia,Bipolar Disorder https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001020 The Center for Genomic Psychiatry at the University of Southern California (USC), SUNY Downstate and an extensive network of academic medical centers have created the Genomic Psychiatry Cohort (GPC). The GPC consists of a large clinical cohort of patients with schizophrenia, bipolar disorder, and healthy controls. The data generation of genotyping and whole genome sequencing of the GPC has been done in collaboration with the USC and the Broad Institute of MIT and Harvard. Genome-wide association studies are being performed with the samples to identify genetic risks for psychiatric disease. Genotyping is also being used to determine ancestry informative markers and replication of candidate genes. Whole genome sequencing identifies functional variants associated with disease risk.
Link
https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001020
Palabras clave
Versiones (1)
- 24/8/23 24/8/23 - Arman Ghanaat
Titular de derechos de autor
Steven McCarroll, PhD, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
Subido en
24 de agosto de 2023
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
dbGaP phs001020 Genomic Psychiatry Cohort (GPC) Whole Genome Sequencing and Genotyping Study
This sample attributes table informs of body site where sample was collected, sample analyte type, sample tumor status, sample histology, whether 30X mean coverage was achieved in the sample during sequencing, and site where sequencing took place.
- StudyEvent: SEV1
- Eligibility Criteria
- This subject consent data table contains subject IDs and consent group information.
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
- This subject phenotype table informs of subject's sex, primary disease, case-control status for schizophrenia or bipolar disorder, and genetically determined ancestry.
- This sample attributes table informs of body site where sample was collected, sample analyte type, sample tumor status, sample histology, whether 30X mean coverage was achieved in the sample during sequencing, and site where sequencing took place.
Similar models
This sample attributes table informs of body site where sample was collected, sample analyte type, sample tumor status, sample histology, whether 30X mean coverage was achieved in the sample during sequencing, and site where sequencing took place.
- StudyEvent: SEV1
- Eligibility Criteria
- This subject consent data table contains subject IDs and consent group information.
- This subject sample mapping data table includes a mapping of study subject IDs to sample IDs. Samples are the final preps submitted for genotyping, sequencing, and/or expression data. For example, if one patient (subject ID) gave one sample, and that sample was processed differently to generate 2 sequencing runs, there would be two rows, both using the same subject ID, but having 2 unique sample IDs.
- This subject phenotype table informs of subject's sex, primary disease, case-control status for schizophrenia or bipolar disorder, and genetically determined ancestry.
- This sample attributes table informs of body site where sample was collected, sample analyte type, sample tumor status, sample histology, whether 30X mean coverage was achieved in the sample during sequencing, and site where sequencing took place.
C1299222 (UMLS CUI [1,2])
C1518422 (UMLS CUI [1,2])
C0007634 (UMLS CUI [1,2])
C0332307 (UMLS CUI [1,3])
C0449560 (UMLS CUI [1,4])
C1292533 (UMLS CUI [1,5])
C4743987 (UMLS CUI [1,2])
C3816446 (UMLS CUI [1,3])
Sin comentarios